Diabetes
Danish pharmaceutical giant Novo Nordisk has announced a plan to invest $4.1 billion (€3.8 billion) to expand its US manufacturing capacity. The new plant will be a second fill and finishing facility for high-in-demand weight loss drugs like Wegovy and Ozempic in Clayton, North Carolina. Novo Nordisk's decision to invest in the US comes as part of its broader strategy to enhance its global manufacturing network. The medical firm states that: "Marking one of the largest manufacturing investments in Novo Nordisk's history, the expansion will add 1.4 million square feet of production space for as...
Euronews (English)
El ayuno intermitente puede ayudar a las personas con diabetes tipo 2 temprana a mejorar sus niveles de azúcar en sangre, perder peso y reducir la presión arterial, según un nuevo estudio. En el ensayo, unos 400 participantes chinos tomaron los antidiabéticos metformina o empagliflozina o siguieron un plan de ayuno intermitente 5:2, en el que ayunaban dos días no consecutivos de la semana y pasaban los otros cinco desayunando y almorzando normalmente y cenando un sustitutivo de la comida. Reducción del nivel de azúcar en la sangreAl final del estudio de 16 semanas, los participantes que adopta...
Euronews (Spanish)
Intermittent fasting may help people with early type 2 diabetes improve their blood sugar levels, lose weight, and lower their blood pressure, according to a new study. For the trial, roughly 400 participants in China either took the antidiabetic medications metformin or empagliflozin or followed a 5:2 intermittent fasting plan, in which people fasted for two nonconsecutive days of the week and spent the other five eating a normal breakfast and lunch and having a meal replacement for dinner. By the end of the 16-week study, participants who adopted the 5:2 diet saw a blood sugar level reductio...
Euronews (English)
For the past year and a half, Tandra Cooper Harris and her husband, Marcus, who both have diabetes, have struggled to fill their prescriptions for the medications they need to control their blood sugar. Without Ozempic or a similar drug, Cooper Harris suffers blackouts, becomes too tired to watch her grandchildren, and struggles to earn extra money braiding hair. Marcus Harris, who works as a Waffle House cook, needs Trulicity to keep his legs and feet from swelling and bruising. The couple’s doctor has tried prescribing similar drugs, which mimic a hormone that suppresses appetite and control...
Kaiser Health News
La compañía registró un beneficio neto de 3.404 millones de euros, frente a los 2.654 millones de euros del mismo período del año pasado. Supera los 3.093 millones de euros anticipados por los analistas. El beneficio por acción también subió hasta 0,76 euros desde los 0,589 euros del año anterior, lo que indicaría una sólida sorpresa del 8,75% con respecto a las expectativas del mercado. Ventas inesperadasLas ventas del trimestre alcanzaron los 8.747 millones de euros, un 22% más que los 7.135 millones de euros de hace un año, 8.490 millones de euros pronosticados por los analistas bursátiles....
Euronews (Spanish)
The company reported a net profit of DKK 25.41 billion (€3.404 billion), up from DKK 19.81 billion (€2.654 billion) in the same period last year and surpassing the DKK 23.09 billion (€3.093 billion) anticipated by analysts. Earnings per share (EPS) also rose to DKK 5.68 (€0.76) from DKK 4.39 (€0.589) a year prior, indicating a robust 8.75% surprise over market expectations. Sales for the quarter reached DKK 65.35 billion (€8.747 billion), a 22% increase from DKK 53.37 billion (€7.135 billion) a year ago, outperforming the DKK 63.43 billion (€8.490 billion) forecast by analysts. Weight-loss dru...
Euronews (English)
Washington (AFP) - Drugs like Ozempic, which have become increasingly popular for losing weight, heighten the risk of certain severe gastrointestinal problems including stomach paralysis, according to a large study published Thursday. The paper, published in the Journal of the American Medical Association (JAMA), looked at a class of drugs called GLP-1 agonists that includes the brands Wegovy, Ozempic, Rybelsus and Saxenda. It then compared the rate of serious side effects to another class of weight loss drug, bupropion-naltrexone. The GLP-1 agonists were associated with an almost four times ...
AFP
By Nidhi Jacob A study00119-5/fulltext) backed by the Indian Council of Medical Research has estimated that in India, 136 million people (which is more than the population of Maharashtra) or 15.3% of the population are likely to be pre-diabetic. There is almost no urban-rural divide when it comes to pre-diabetes with 15.4% of the urban population and 15.2% of rural India in the pre-diabetic stage. Diabetes is a major cause of blindness, kidney failure, heart attacks, stroke and lower limb amputation, according to the World Health Organization. Pre-diabetes is a condition in which a person's bl...
BOOM Live
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら